Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer

Current Opinion in Oncology

Volumn 12, Issue 6, 2000, Pages 550-556

  Scheffer, George L ^a   Schroeijers, Anouk B ^a   Izquierdo, Miguel A ^b   Wiemer, Erik A C ^c   Scheper, Rik J ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; EPIRUBICIN; GLYCOPROTEIN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL;

CANCER RESISTANCE; DRUG SENSITIVITY; HUMAN; LUNG RESISTANCE; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

ANIMALS; CRYOELECTRON MICROSCOPY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; RATS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0034501399     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200011000-00007     Document Type: Review

References (72)

1. Clinical multidrug resistance in cancer: A multifactorial problem
2. ABC transporters: From microorganisms to man
3. P-glycoprotein: A mediator of multidrug resistance in tumour cells
4. The multidrug resistance protein family
5. A multidrug resistance transporter from human MCF-7 breast cancer cells
6. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
7. Anti topoisomerase drug action and resistance
8. The drug resistance-related protein LRP is the human major vault protein
9. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA
10. Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes
11. Vaults. III. Vault ribonucleo-protein particles open into flower-like structures with octagonal symmetry
12. Structure of the vault, a ubiquitous celular component
13. RNA location and modeling of a WD40 repeat domain within the vault
14. Vaults and telomerase share a common subunit, TEP1
15. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase
16. Mammalian telomeres and telomerase
17. Reconstitution of human telomerase activity in vitro
18. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT
19. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability
20. The nuclear protein PH5P of the interalpha-inhibitor superfamily: A missing link between poly(ADP-ribose)polymerase and the inter-alpha- inhibitor family and a novel actor of DNA repair?
21. Identification of a novel gene (ADPRTL1) encoding a potential Poly(ADP- ribosyl)transferase protein
22. Poly(ADP-ribose) polymerase: Molecular biological aspects
23. Poly(ADP-ribose) polymerase: A molecular nick-sensor
24. Cellular responses to DNA damage in the absence of Poly(ADP-ribose) polymerase
25. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase
26. Vaults are up-regulated in multidrug-resistant cancer cell lines
27. Vault ribonucleoprotein particles from rat and bullfrog contain a related small RNA that is transcribed by RNA polymerase III
28. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex
29. Characterization of the sea urchin major vault protein: A possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport
30. Recombinant major vault protein is targeted to neuritic tips of PC12 cells
31. Axonal transport of ribonucleoprotein particles (vaults)
32. Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell
33. The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines
34. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors
35. Upregulation of vaults, Pgp and MRP1 during dendritic cell development: A physiological role for vaults in dendritic cell differentiation
36. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines
37. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells
38. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis
39. Membrane transport proteins associated with drug resistance expressed in human melanoma
40. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines
41. Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues
42. Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance
43. Expression of mdr1/P-glycoprotein and p110 in neuroblastoma
44. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
45. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
46. Multifactorial drug-resistance phenomenon in acute leukemias: Impact of P170-MDR1, LRP56 protein, glutathione-transferases and metallothionein systems on clinical outcome
47. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival
48. The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia
49. Drug resistance factors in acute myeloid leukemia: A comparative analysis
50. Expression of the human major vault protein LRP in acute myeloid leukemia
51. High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone
52. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias
53. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia
54. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications
55. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
56. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
57. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: A critical evaluation by three techniques
58. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells
59. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma
60. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma
61. The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma
62. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in child-hood acute lymphoblastic leukemia
63. Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia
64. Expression of multidrug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia
65. Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia
66. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
67. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma
68. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
69. Expression of the lung resistance protein (LRP) in primary breast cancer
70. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis
71. Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes